Journal
TRENDS IN MOLECULAR MEDICINE
Volume 16, Issue 12, Pages 574-583Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2010.08.006
Keywords
-
Funding
- National Cancer Institute/National Institutes of Health (NCI/NIH) [R21 CA121842]
- NCI In vivo Cellular and Molecular Imaging Centers (ICMIC) [P50]
- NCI Center for Cancer Nanotechnology Excellence [U54 CA119367]
Ask authors/readers for more resources
Near-infrared fluorescence (NIRF) imaging promises to improve cancer imaging and management; advances in nanomaterials allow scientists to combine new nanoparticles with NIRF imaging techniques, thereby fulfilling this promise. Here, we present a synopsis of current developments in NIRF nanoprobes, their use in imaging small living subjects, their pharmacokinetics and toxicity, and finally their integration into multimodal imaging strategies. We also discuss challenges impeding the clinical translation of NIRF nanoprobes for molecular imaging of cancer. Whereas utilization of most NIRF nanoprobes remains at a proof-of-principle stage, optimizing the impact of nanomedicine in cancer patient diagnosis and management will probably be realized through persistent interdisciplinary amalgamation of diverse research fields.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available